搜索
Roivant Sciences Ltd
ROIV添加自选
38.880USD
+2.260+6.17%
收盘 11-06 16:00（美东）
28.08B总市值
亏损市盈率 TTM
盘后交易 17:02 (美东)38.930USD+0.080+0.21%
盘后交易 17:02 (美东)关于 Roivant Sciences Ltd 公司
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Sciences Ltd 简介
公司代码ROIV
公司名称Roivant Sciences Ltd
上市日期Dec 03, 2020
CEOVenker (Eric)
员工数量750
证券类型Ordinary Share
年结日Dec 03
公司地址7Th Floor, 50 Broadway
城市LONDON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United Kingdom
邮编SW1H 0DB
电话4412955950
网址http://roivant.com/
公司代码ROIV
上市日期Dec 03, 2020
CEOVenker (Eric)
Roivant Sciences Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.74M
+0.29%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.74M
+0.29%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
973.50K
-41.09%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
973.50K
-41.09%
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
218.48K
-18.45%
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
218.48K
-18.45%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
186.47K
-10.71%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
186.47K
-10.71%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
109.97K
+0.74%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
109.97K
+0.74%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.74M
+0.29%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.74M
+0.29%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
973.50K
-41.09%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
973.50K
-41.09%
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
218.48K
-18.45%
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
218.48K
-18.45%
常见问题
Roivant Sciences Ltd的前五大股东是谁？
Roivant Sciences Ltd 的前五大股东如下：Dr. Keith S. Manchester, M.D.
有多少机构持有Roivant Sciences Ltd(ROIV)的股份？
截至2026Q1，共有781家机构持有Roivant Sciences Ltd的股份，合计持有的股份价值约为565.52M，占公司总股份的79.01%。与2025Q4相比，机构持股有所增加，增幅为-23023750.00。